Tenax Therapeutics, Inc. (TENX) Stock Grade

About Tenax Therapeutics, Inc.'s fundamentals

Tenax Therapeutics is a biotechnology company with a market capitalization of $478.1 million that reported no revenue growth year-over-year and a net loss in its latest annual statement, reflecting the typical financial profile of a development-stage biotech firm. The company generated no net income, resulting in a 0.0% net margin, and does not currently pay a dividend. Traditional valuation metrics like the P/E ratio and return on equity are not applicable given the company's unprofitable status.